Hitachi In vitro diagnostic (IVD) analyzers

Hitachi 3/30/98 In vitro diagnostic analyzers

1. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a) (4). This would be a violation of the 1978 Good Manufacturing Practices Regulation, 21 CFR 820.162, inadequate failure investigation. For example, software release versions were not documented as required or verified to demonstrate that the revisions to the software corrected the problem. Additional deficiencies pertaining to corrective and preventative action include the following:

a. inadequate corrective action to address a recurring software problem with the BM/Hitachi 917 analyzers, resulting in four problem reports to the firm;

Upcoming Training

62304, FDA, and Emerging Standards for Medical Device and HealthIT

Instructors:  Brian Pate, John F. Murray, Jr
Location: Sunnyvale, CA, USA
Dates:  February 4-6, 2020
Registration Link

Receive $300 discount with Premium-Individual subscription purchase (or $333 per person for Premium-Company subscription)!  Email
to receive discount

QSS Software Validation
Planned Instructors:  Brian Pate, John F. Murray, Jr
Location: Boston, MA, USA
Dates:  June 2-4, 2020
Registration Link

Corporate Office

15148 Springview St
Tampa, FL 33624
Partners located in the US (CA, FL, MA, MN) and Italy.